ICURE PHARMACEUTICAL INCORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,915 KRW | -0.36% |
|
+1.06% | -8.37% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 202,382 | 233,040 | 467,315 | 338,828 | 79,498 | 78,103 |
| Enterprise Value (EV) 1 | 169,929 | 281,230 | 512,394 | 388,597 | 112,722 | 145,953 |
| P/E ratio | -23 x | -26 x | -34.9 x | -8.6 x | -1.42 x | -2.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.07 x | 3.83 x | 5.18 x | 5.27 x | 1.34 x | 1.37 x |
| EV / Revenue | 5.1 x | 4.62 x | 5.68 x | 6.05 x | 1.9 x | 2.57 x |
| EV / EBITDA | -21 x | -102 x | -60.2 x | -17.4 x | -5.97 x | -7.81 x |
| EV / FCF | -8.68 x | -3.8 x | -14 x | -13.8 x | 13.1 x | -7.83 x |
| FCF Yield | -11.5% | -26.3% | -7.15% | -7.26% | 7.64% | -12.8% |
| Price to Book | 2.39 x | 2.34 x | 4.17 x | 3.56 x | 1.06 x | 1.34 x |
| Nbr of stocks (in thousands) | 17,636 | 18,566 | 21,363 | 22,340 | 31,115 | 37,370 |
| Reference price 2 | 11,476 | 12,552 | 21,875 | 15,167 | 2,555 | 2,090 |
| Announcement Date | 3/14/19 | 3/12/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 33,320 | 60,922 | 90,144 | 64,283 | 59,367 | 56,806 |
| EBITDA 1 | -8,104 | -2,755 | -8,510 | -22,341 | -18,872 | -18,682 |
| EBIT 1 | -8,820 | -6,376 | -15,534 | -30,119 | -27,087 | -27,725 |
| Operating Margin | -26.47% | -10.47% | -17.23% | -46.85% | -45.63% | -48.81% |
| Earnings before Tax (EBT) 1 | -7,687 | -8,513 | -11,498 | -38,835 | -43,090 | -32,525 |
| Net income 1 | -7,885 | -8,751 | -12,614 | -38,167 | -41,766 | -31,420 |
| Net margin | -23.66% | -14.36% | -13.99% | -59.37% | -70.35% | -55.31% |
| EPS 2 | -498.6 | -481.9 | -626.7 | -1,763 | -1,793 | -837.0 |
| Free Cash Flow 1 | -19,583 | -74,057 | -36,644 | -28,205 | 8,609 | -18,632 |
| FCF margin | -58.77% | -121.56% | -40.65% | -43.88% | 14.5% | -32.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/12/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 |
|---|---|
| Net sales 1 | 15.64 |
| EBITDA | - |
| EBIT 1 | -4.896 |
| Operating Margin | -31.31% |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 5/15/23 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 48,190 | 45,079 | 49,769 | 33,224 | 67,851 |
| Net Cash position 1 | 32,453 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -17.49 x | -5.297 x | -2.228 x | -1.761 x | -3.632 x |
| Free Cash Flow 1 | -19,583 | -74,057 | -36,644 | -28,205 | 8,609 | -18,632 |
| ROE (net income / shareholders' equity) | -15.1% | -9.37% | -11.3% | -36% | -44.7% | -42.7% |
| ROA (Net income/ Total Assets) | -6.3% | -2.41% | -4.77% | -9.17% | -7.7% | -8.88% |
| Assets 1 | 125,085 | 362,772 | 264,437 | 416,247 | 542,231 | 353,821 |
| Book Value Per Share 2 | 4,802 | 5,363 | 5,250 | 4,255 | 2,400 | 1,558 |
| Cash Flow per Share 2 | 114.0 | 439.0 | 277.0 | 791.0 | 1,353 | 169.0 |
| Capex 1 | 11,564 | 62,250 | 22,996 | 5,701 | 4,197 | 2,225 |
| Capex / Sales | 34.7% | 102.18% | 25.51% | 8.87% | 7.07% | 3.92% |
| Announcement Date | 3/14/19 | 3/12/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.37% | 51.99M | |
| -3.33% | 249B | |
| +10.09% | 18.86B | |
| 0.00% | 17.37B | |
| -1.32% | 10.65B | |
| -7.73% | 10.26B | |
| +3.86% | 6.72B | |
| +9.76% | 5.94B | |
| -0.06% | 4.55B | |
| -16.98% | 3.83B |
- Stock Market
- Equities
- A175250 Stock
- Financials Icure Pharmaceutical Incorporation
